Quintrio
Home

SERVICES-HEALTH SERVICES

Privia Health Group, Inc. Common Stock

PRVA

Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.

Last trade $25.22
Day change -$0.04 (-0.16%)
Day range $23.91 – $26.14
Volume 517,212
Market cap $3.23B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.23B
Price / earnings
92.88×
Price / book
3.96×
Price / sales
1.33×
EV / sales
1.14×
EV / EBITDA
1.4×

Profitability

Earnings per share
$0.27
Return on assets
2.22%
Return on equity
4.26%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.63×
Quick ratio
1.63×
Cash ratio
0.66×

Cash flow

Price / cash flow
29.86×
Price / free cash flow
29.86×
Free cash flow
$108.07M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PRVA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$656.96M$632.63M$603.85M$541.17M$580.42M$521.15M$480.1M$460.9M
Cost of revenue$69.67M$69.36M$68.42M$66.85M$61.44M$64.92M$59.53M$59.77M
Gross profit$587.29M$563.27M$535.43M$474.33M$518.98M$456.24M$420.57M$401.13M
Selling, general and administrative$44.39M$47.66M$49.61M$35.72M$46.6M$44.32M$38.64M$40.89M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$47.9M$51.02M$52.89M$38.38M$49.37M$46.91M$40.54M$42.72M
Operating income$539.4M$512.26M$482.54M$435.95M$469.61M$409.33M$380.03M$358.41M
Interest expense$1.72M$1.67M$0$0$2.27M$2.41M$0$0
Income before taxes$22.27M$16.75M$9.31M$13.37M$16.67M$5.74M$8.15M$8.02M
Income taxes$7.67M$7.02M$5.6M$2.79M$6.87M$2.46M$2.1M$2.66M
Net income$14.59M$9.73M$3.71M$10.59M$9.81M$3.29M$6.05M$5.37M
Net income attributable to common shareholders$13.49M$9.05M$3.06M$9.15M$6.86M$2.69M$4.22M$4.4M
EBITDA$542.9M$515.61M$485.82M$438.61M$472.38M$411.91M$381.93M$360.24M
Basic earnings per share$0.11$0.07$0.02$0.07$0.06$0.02$0.03$0.04
Diluted earnings per share$0.10$0.07$0.02$0.07$0.05$0.02$0.03$0.03

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

3 Reasons Why Growth Investors Shouldn't Overlook Privia Health (PRVA)

Privia Health (PRVA) is highlighted as a strong growth stock pick with a Zacks Rank #2 (Buy) and Growth Score of B. The company demonstrates impressive fundamentals including projected EPS growth of 48.6% (vs. industry average of 28.1%), superior asset utilization ratio of 1.67, expected sales growth of 16.1%, and positive earnings estimate revisions. These metrics position the stock well for outperformance among growth investors.

Zacks Investment Research

Privia Health (PRVA) Q3 Earnings and Revenues Top Estimates

Privia Health reported Q3 2026 earnings of $0.10 per share, beating consensus estimates of $0.09, with revenues of $656.96 million exceeding expectations by 9.57%. However, the stock has underperformed the S&P 500 by 17.8% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Hims & Hers Health, a peer in the Medical Info Systems industry, is expected to report results on November 9.

GlobeNewswire Inc.

Privia Health Reports Strong Third Quarter and Year-to-Date 2026 Results

Privia Health Group announced robust third-quarter 2026 financial results with YTD net income of $25.6M (+85.9%) and adjusted EBITDA of $114.7M (+21.9%). The company raised its full-year 2026 guidance above the high end for all key metrics. Privia expanded its value-based care footprint by acquiring American Choice Healthcare MSSP business for ~$36M, adding 36,000 attributed lives across 13 states, while exiting its Montana partnership effective January 2027.

GlobeNewswire Inc.

Global Value-Based Healthcare Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

The value-based healthcare market is experiencing robust growth, projected to reach USD 62 billion by 2034 from USD 16.5 billion in 2025, with a CAGR of ~16%. The shift from fee-for-service to outcome-based payment models is driven by rising healthcare costs, chronic disease burden, and government reimbursement reforms. North America dominates with 72% market share, while Asia-Pacific is expected to record the fastest growth. Key players include Optum, Humana, Evolent Health, Agilon Health, and Privia Health.

The Motley Fool

Is Privia Health Stock a Buy After Hedge Fund Rubicon Founders Added Over 175,000 Shares to Its Position?

Hedge fund Rubicon Founders increased its stake in Privia Health Group by 175,142 shares in Q1 2026, with the stock now representing 88.92% of the fund's portfolio. The move signals bullish sentiment, supported by Privia's strong financial performance including 26% YoY revenue growth in Q1 2026 and 59% net income growth in 2025, positioning it as a worthwhile long-term investment.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.